HeraMED (ASX:HMD) Other Long-Term Liabilities: A$0.00 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is HeraMED Other Long-Term Liabilities?

HeraMED ASX:HMD Other Long-Term Liabilities is A$0.00 Mil as of Dec. 2025. The stock has 2 warning signs investors should review.

HeraMED's other long-term liabilities for the quarter that ended in Dec. 2025 was A$0.00 Mil.

HeraMED's quarterly other long-term liabilities increased from Dec. 2024 (A$0.00 Mil) to Jun. 2025 (A$0.49 Mil) but then declined from Jun. 2025 (A$0.49 Mil) to Dec. 2025 (A$0.00 Mil).

HeraMED's annual other long-term liabilities declined from Dec. 2023 (A$0.76 Mil) to Dec. 2024 (A$0.00 Mil) but then increased from Dec. 2024 (A$0.00 Mil) to Dec. 2025 (A$0.00 Mil).

HeraMED Other Long-Term Liabilities Related Terms

HeraMED Other Long-Term Liabilities Historical Data

* Premium members only.

The historical data trend for HeraMED's Other Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

HeraMED Other Long-Term Liabilities Chart

HeraMED Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Long-Term Liabilities
Get a 7-Day Free Trial 0.76 0.74 0.76 0.00 0.00

HeraMED Semi-Annual Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Other Long-Term Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.76 0.63 0.00 0.49 0.00

HeraMED Other Long-Term Liabilities Calculation

Other Long-Term Liabilities are the other liabilities on the balance sheet that do not need to be repaid within the next 12 months, but still need to be repaid over time. For instance, on Wal-Mart's balance sheet, there are items called Long Term obligations under capital leases, deferred income taxes, and redeemable non-controlling interest. These are all Other Long-Term Liabilities.

What does a Other Long-Term Liabilities of A$0.00 Mil mean?
HeraMED (ASX:HMD) has a Other Long-Term Liabilities of A$0.00 Mil as of Dec. 2025. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on HeraMED and its competitors.
Is HeraMED's Other Long-Term Liabilities too high?
HeraMED's current Other Long-Term Liabilities is A$0.00 Mil.
How does HeraMED's Other Long-Term Liabilities compare to ABT and SYK?
HeraMED's Other Long-Term Liabilities of A$0.00 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Long-Term Liabilities for a Medical Devices & Instruments company?
A good Other Long-Term Liabilities depends on the Medical Devices & Instruments industry context. However, Other Long-Term Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Long-Term Liabilities mean?
A high Other Long-Term Liabilities can signal that a stock is expensive relative to its fundamentals. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on HeraMED and its competitors. HeraMED's current Other Long-Term Liabilities is A$0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HeraMED stock overvalued right now?
Based on GuruFocus' analysis, HeraMED (ASX:HMD) is currently considered Significantly Overvalued. The stock's GF Value™ is A$0.02, compared to a current price of A$0.04 — trading 90% above its estimated fair value. The current Other Long-Term Liabilities is A$0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Long-Term Liabilities calculated?
Other Long-Term Liabilities is calculated from a company's financial statements. For HeraMED (ASX:HMD), the current Other Long-Term Liabilities is A$0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

HeraMED Business Description

Other Exchanges 1I4:Germany
Address 117 Camberwell Road, Level 1 - Suite 1, Hawthorn East, Melbourne, VIC, AUS, 3123
HeraMED Ltd is a medical data and technology company providing the digital transformation of maternity care by revolutionizing the prenatal and postpartum experience with its hybrid maternity care platform. It offers a proprietary platform that utilizes hardware and software to reshape the Doctor/Patient relationship using its clinically validated in-home foetal and maternal heart rate monitor, HeraBEAT, cloud computing, artificial intelligence. Its offering, HeraCARE, has been engineered to offer a fully integrated maternal health ecosystem designed to deliver care at a lower cost, ensure expectant mothers are engaged, informed and well-supported, and allow healthcare professionals to provide the care and enable early detection and prevention of potential risks.